5-Amino-1MQ: NNMT Inhibition, Adipocyte Metabolism, and Body Composition Research

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide — it is a quinolinium compound with a molecular weight under 200 Da — and it is grouped with metabolic peptides in clinical practice because it appears in the same body-composition protocols, not because it shares their chemistry. That distinction matters for how it is dosed, how it is formulated, and how its safety profile should be assessed.

The NNMT Target

What NNMT Does

Nicotinamide N-methyltransferase catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine. The reaction has two consequences that both matter metabolically:

• It removes nicotinamide from the NAD+ salvage pathway. Nicotinamide that gets methylated cannot be recycled back into NAD+.
• It consumes SAM, the cell's principal methyl donor.

Why NNMT Became a Metabolic Target

NNMT expression is elevated in the adipose tissue of obese and insulin-resistant subjects, and in several models correlates with the degree of metabolic dysfunction. The hypothesis that followed is straightforward: if elevated NNMT is depleting adipocyte NAD+ and consuming methyl donors, inhibiting it should raise adipocyte NAD+ availability, restore sirtuin signaling, and increase energy expenditure in fat tissue specifically.

Relationship to NAD+ Biology

5-Amino-1MQ approaches NAD+ availability from the opposite direction to precursor supplementation. Rather than supplying more raw material, it reduces the enzymatic drain on the existing salvage pathway — and does so preferentially in the tissue where NNMT is most overexpressed. That tissue selectivity is the mechanistic argument for it.

Preclinical Research

Adipocyte and Rodent Data

The foundational work comes from Neelakantan, Kannt, and colleagues. In diet-induced obese mice, NNMT inhibition was reported to reduce fat mass and adipocyte size without a corresponding reduction in food intake — pointing to an energy-expenditure effect rather than an appetite effect. Associated observations included increased adipocyte NAD+ and SAM, elevated sirtuin activity, and improvements in metabolic markers.

Related work has reported effects on muscle stem cell function and on myotube differentiation in aged models, extending the interest beyond adipose tissue.

The State of Human Evidence

This is the point requiring the most clarity: there is no published, peer-reviewed, controlled human clinical trial of 5-Amino-1MQ demonstrating fat loss. The compound's reputation rests on rodent and cell-culture data plus practitioner-reported observation.

The mechanistic rationale is coherent and the preclinical results are genuinely interesting. Neither is a substitute for human data, and patients should be told which one they are relying on. Our review of the clinical trial status and fat-loss mechanism covers the published literature in detail.

Administration in Practice

This section describes patterns reported in compounded practice. It is educational context, not a dosing recommendation — administration should be determined by a licensed prescriber.

Oral Delivery

Unlike the injectable peptides it is often stacked with, 5-Amino-1MQ is a small molecule and is administered orally, typically as a capsule. This is a direct consequence of its size and structure.

Reported Frameworks

Practitioner protocols commonly describe daily oral administration in the range of 50–150 mg, taken in the morning, with courses running roughly eight to twelve weeks before a break. Cycling is standard practice rather than continuous use. These figures reflect what is described in compounded practice, not a validated therapeutic range — no dose-ranging human trial has established one.

Stacking Patterns

It appears in protocols alongside GLP-1 receptor agonists, growth hormone secretagogues, and lipotropic compounds. Because the mechanisms differ — appetite and gastric emptying for GLP-1s, GH axis for secretagogues, methyl-donor and lipid transport for lipotropics — the rationale is complementary rather than redundant. Our overview of peptides for fat loss situates it among those options.

Safety Considerations

Reported Effects

Practitioner-reported effects include increased heart rate or palpitations, appetite changes, sleep disturbance when taken later in the day, gastrointestinal upset, and headache. Our detailed review of 5-Amino-1MQ side effects, heart rate, and appetite examines these reports.

The Methylation Consideration

Inhibiting NNMT means less SAM is consumed by that reaction, which alters methyl-group flux. The theoretical implications of chronic NNMT inhibition on broader methylation-dependent processes — including DNA and histone methylation — have not been characterized in humans. This is a reason cycling is prudent rather than merely conventional.

What Long-Term Data Do Not Exist

NNMT is expressed in liver, adipose tissue, and other organs, and its physiological roles beyond nicotinamide clearance are incompletely mapped. There is no long-term human safety data for sustained NNMT inhibition. Patients with hepatic impairment, cardiovascular disease, or on methylation-sensitive medications warrant particular caution. Pregnancy and lactation have no supporting data.

Sourcing and Regulatory Status

5-Amino-1MQ is not an FDA-approved drug product and is widely sold through research-chemical channels where identity and purity are unverified. Where a physician determines it is appropriate, sourcing through a 503A compounding pharmacy with analytical verification is materially different from an unregulated supplier. Current compounding status is tracked on our FDA peptide status tracker.

Frequently Asked Questions About 5-Amino-1MQ

What is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), studied for its effects on adipocyte metabolism, cellular NAD+ availability, and body composition. Despite frequently appearing alongside peptides in metabolic protocols, it is not a peptide.

What is a typical 5-Amino-1MQ dosage?

Practitioner protocols commonly describe 50–150 mg taken orally once daily in the morning, in cycles of roughly eight to twelve weeks. No human dose-ranging trial has validated this range, and dosing should be determined by the prescribing provider.

Does 5-Amino-1MQ actually work for fat loss?

Rodent studies report reduced fat mass and adipocyte size without reduced food intake, which is a meaningful preclinical result. There is no published controlled human trial demonstrating fat loss. Anyone considering it should understand that the evidence is preclinical and mechanistic rather than clinical.

What are the side effects of 5-Amino-1MQ?

Practitioner-reported effects include elevated heart rate or palpitations, appetite changes, sleep disturbance with later dosing, gastrointestinal upset, and headache. Because human trial data are absent, the side-effect profile is not systematically characterized.

Is 5-Amino-1MQ a peptide?

No. It is a quinolinium small molecule of under 200 Da, taken orally. It is grouped with metabolic peptides because it appears in the same protocols, not because of any structural or mechanistic similarity.

How does 5-Amino-1MQ compare with GLP-1 medications?

They work through unrelated mechanisms. GLP-1 receptor agonists such as semaglutide and tirzepatide act on appetite signaling and gastric emptying and are supported by large controlled human trials. 5-Amino-1MQ targets adipocyte energy expenditure via NNMT inhibition and has no comparable human evidence base. They are not equivalent options.

Positioning 5-Amino-1MQ

5-Amino-1MQ is a mechanistically well-reasoned compound at an early stage of evidence. NNMT is a legitimate metabolic target, the preclinical adipose data are consistent, and the tissue-selectivity argument is sound. What does not yet exist is any controlled human trial, dose-ranging study, or long-term safety data — and the gap between "coherent mechanism in mice" and "effective and safe in patients" is exactly where compounds most often fail. Providers considering it for a patient should present it in those terms and source it accordingly.